PEPGEN INC. Additional Paid in Capital, Common Stock
PEPGEN INC. (PEPG) had Additional Paid in Capital, Common Stock of $516.34 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $516.34M.
- 2026-03-31: Additional Paid in Capital, Common Stock $512.91M.
- 2025-12-31: Additional Paid in Capital, Common Stock $508.54M.
- 2025-09-30: Additional Paid in Capital, Common Stock $505.94M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $516.34M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $512.91M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $508.54M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $505.94M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $395.95M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $393.49M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $390.06M 10-K · filed 2026-03-04 |
| 2024-09-30 | $386.58M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $382.95M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $378.54M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $289.87M 10-K · filed 2025-02-24 |
| 2023-09-30 | $287.91M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $285.97M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $284.04M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $282.57M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | $280.99M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $279.63M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $2.47M 10-Q · filed 2022-06-16 |
| 2021-12-31 | $1.65M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |